Is Eisai Co., Ltd. (ESAIY) a Buy, Sell, or Hold?
OTC : ESAIY
Eisai Co., Ltd. — News
$6.8 USD
-$0.03 (-0.44%)
- Volume
- 2.31K
- Average Volume
- 230.2K
- Market Capitalization
- $7.68B
- P/E Ratio
- 32.78
- Dividend Yield
- 3.57%
- Price Target
- Year High
- $9.22
- Year Low
- $5.69
- Day High
- —
- Day Low
- —
- Payout Ratio
- $1.17
- Current Ratio
- $2.24
| Source | Headline |
|---|---|
|
FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug
The U.S. FDA on Monday approved an at-home starting dose of Eisai's and Biogen's Alzheimer's drug, allowing some patients to begin therapy with injections administered by themselves or a caregiver. reuters.com - 2026-07-13 15:02:12 |
|
Eisai Co., Ltd. (ESAIY) Analyst/Investor Day Transcript
Eisai Co., Ltd. (ESAIY) Analyst/Investor Day Transcript seekingalpha.com - 2026-05-25 10:47:04 |
|
Eisai Co., Ltd. (ESAIY) Q4 2026 Earnings Call Transcript
Eisai Co., Ltd. (ESAIY) Q4 2026 Earnings Call Transcript seekingalpha.com - 2026-05-15 12:50:46 |
|
Merck-Eisai's combination cancer therapy fails to meet main goals of late-stage study
Merck and Eisai's experimental combination treatments for a type of kidney cancer failed to meet the main goals of a late-stage study, the companies said on Tuesday. reuters.com - 2026-04-21 06:53:05 |
